Vesper Bio is a clinical-stage biotech company specializing in exploiting sortilin receptor biology. They use a sortilin inhibitor to rebalance progranulin levels, addressing critical unmet medical needs. Pioneers in sortilin biology, Vesper Bio's approach is grounded in decades of exploration of the Vps10p protein family's structure and function. They focus on discovering protein-protein interaction inhibitors, informed by high-resolution ligand-target X-ray co-crystal structures and collaborations with academic labs. The company boasts a strong background in biopharma and is supported by a multinational scientific advisory board with key opinion leaders.